





clinical findings consistent with
JDM were found. Her condition
improved with steroids, cytotoxic
therapy and physiotherapy. Some
investigation and treatment
modalities could not be accessed for
the benefit of the patient. Although,
the outcome of patients with JDM
has improved with the discovery of
steroids, the disease is shown to
have a variable course, with
attendant social and financial
implications especially to the
immediate family.
Summary A case of Juvenile
dermatomyositis (JDM) in a 10
year old Nigerian girl is herein
reported to discuss some of the
features of the disease and
challenges in management of such
a rare but crippling autoimmune
vasculopathy of childhood. She
was referred to the University of
Maiduguri Teaching Hospital
(UMTH) with an eight-month
history of recurrent fever,
abdominal pain, and a four-month
history of body rash and inability
to walk or sit. Muscle biopsy and
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rapid onset of symptoms and gastrointestinal tract
involvement.
We report a case of JDM in a Nigerian girl which to
the best of our knowledge has not been previously
reported in Nigeria probably because of its rarity or
because it was usually missed by clinicians. Some of
the features disease and challenges encountered in
management are also highlighted.
HUA was a 10 year old primary school girl referred
from a general hospital to University of Maiduguri
Teaching Hospital (UMTH) with an eight month
history of recurrent fever, abdominal pain, and facial
puffiness, four months history of body rash,
dysphonia and inability to walk or sit. Prior to
referral, she was being treated at the referring facility
for acute glomerulonephritis (AGN) and anaemia,
where she had received blood transfusion and other
medications without improvement. Although, a




Juvenile dermatomyositis (JDM) is the most common
childhood inflammatory myopathy. It is a systemic,
autoimmune inflammatory muscle disorder and
vasculopathy that affects children younger than 18
years, primarily affecting the skin and the skeletal
muscles. Characteristic findings include Gottron
papules, a heliotrope rash, calcinosis cutis, and
symmetrical proximal muscle weakness.
An estimated annual incidence of 3.4, 3.3 and 2.7
cases per million children were reported in whites,
blacks and Hispanics respectively, and a female to
male ratio of 2.3:1 and 5:1 in the United States and
United Kingdom respectively. The median age of
onset of JDM is 6.8 years in girls and 7.3 years in
boys, with a median diagnosis delay of 3-4 months.
Prior to the advent of corticosteroids, the prognosis
was poor. Brunsting and Banker types of JDM have
been described in children, with the former type
characterized by slow progression and better





Skeletal muscle CK iso-enzyme analysis was not
done due to non availability of the reagents. Other
immunologic tests such as anti-nuclear antibody,
myositis associated autoantibody were not done due
unavailability in our centre. Stool for occult blood,
urine microscopy, culture and sensitivity were
negative. Complete blood count and serum
electrolytes, urea and creatinine were not remarkable.
Histology of incisional muscle biopsy from the right
upper thigh demonstrated focal areas of
inflammation, necrosis, few myofibre fragmentation
as well as atrophy and fibrin which are in keeping
with JDM (Fig 2).
She was commenced on prednisolone 2mg/kg/24hr
and four weeks later, weekly methotrexate 15mg/m
was added because of slow response to the steroid.
Following resolution of muscle pain and tenderness,
physiotherapy was commenced. The patient
responded to the treatment with resolution of the
fever; headache, muscle pain and desquamation and
healing of skin eruptions. She regained ability to feed
herself and was able to sit unsupported for up to an
hour. About a week after initial improvement, she
developed high grade continuous fever and anorexia.
Sepsis work up was done, but no organism was
isolated and no focus for the infection was found. She
was given anti-malarial and antibiotic medications to
no avail. HUA subsequently died two weeks
following the onset of the fever.
The diagnosis of JDM is challenging especially in a
developing country like Nigeria where adequate
facilities, equipment and expertise may be lacking. In
1975, Bohan and Peter proposed criteria for the
diagnosis of JDM. These criteria include
characteristic skin rash, proximal muscle weakness,
elevated muscle enzymes, myopathic changes on
electromyography and abnormal muscle biopsy
findings. Typical skin findings in combination with
Fig 2
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Photomicrograph showing myofibre necrosis, atrophy and
lymphocytic infiltrates: MG X 200). Radiograph of the upper
arms showed no evidence of calcifications.
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symptoms was obtained, no history of change in
urinary frequency, volume or colour was found.
There was also no history of haematuria or dark
coloured urine. The body rash was more on the upper
torso, extensor surfaces of both upper and lower
limbs and the buttocks. No associated joint swelling
or pain but there was generalised body ache with
classical history of proximal muscle weakness that
Progressed to inability to walk, sit-up and hold the
neck. At about the same time, she was noticed have
nasal quality speech with occasional regurgitation of
fluid via the nose. She had no preceding history of
exposure to vaccines, drugs or insect bite. HUA was
not a known sickle cell disease patient and had no
history suggestive of diabetes mellitus. There was no
family history of such or similar presentation.
On admission, physical examination revealed a
chronically ill looking pale, girl with facial puffiness
but was afebrile, not jaundiced and had no significant
peripheral lymphadenopathy. Her weight was 26kg
(80% of expected for age) and her length was 137cm
(100% of expected for age). The main findings were
in the musculoskeletal system which revealed
generalised body tenderness. She was unable to raise
her arms even to feed herself. She was curled up
almost in a foetal position, unable to sit and had some
contractures at the elbow and the knee joints.
Maculopapular skin eruptions were observed in the
upper torso, extensor surfaces of arms and legs and
the buttocks. A crop of peri-orbital eruptions was
noted below the right medial canthus (heliotrope) and
the skin over the metacarpal and proximal
interphalengeal joints fitting the pattern of typical
Gottron papules.
The lesions were hypertrophied and erythematous
Although, no subcutaneous mass or swelling was
found, an ulcer on the right elbow measuring 2x3cm
in diameter with lobulated floor was noted. Diagnosis
of Juvenile Dermatomyositis (JDM) was
entertained. Blood pressure and urinalysis remained
normal throughout the period of admission. HIV
antibody test and Rheumatoid factor were negative.
Antistreptolysin O titre was positive (400 IU) but




The fact that the biopsy was not guided by MRI
probably suggest extensive muscle involvement in
the patient. Other evidence of severe disease in the
patient include nasal speech and regurgitation of
liquids through the nose and gastrointestinal tract
symptoms.
Calcifications occur in 20-40% of children with
dermatomyositis and is implicated in increasing the
morbidity and mortality of the disease. In JDM,
calcifications are more frequent at anatomic sites that
are normally exposed to daily minor trauma but not
usually mineralized, such as the elbows or behind the
knees. Calcinosis on the other hand, is seen as
crusted papules or plaques around joints or as non-
healing sores. The intractable ulcers at the elbows in
the patient may suggest the existence of calcinosis.
Sometimes, the calcified material is extruded through
the skin as a white cheesy exudate, leaving behind a
dry pitted scar. Muscle calcification results in
contractures or severe muscular pain. Calcinosis is
thought to be dystrophic, as damaged muscles release
mitochondrial calcium into matrix vesicles that
promote mineralization. Calcinosis lesions are rarely
present at diagnosis but are usually found later during
the course of the disease. Delayed treatment and
severe disease have been reported as risk factors for
development of calcinosis.
The goals of treatment include control of
inflammation manifesting as pain, muscle weakness,
skin lesion and prevention and management of short
term and long term complications of the disease and
treatment. The main stay of therapy is steroids. For
severe and refractory cases, intravenous methyl
prednisolone can be given. Second line drugs
methotrexate, cyclosporine, azathioprine and
h y d r o x y c h l o r o q u i n e . C y c l o s p o r i n a n d
hydroxychloroquine are reported to be effective
especially for skin involvement. Intravenous
immunoglobulin (IVIG) may be indicated by relapse,
incomplete response, or for steroid sparing purposes,
the addition of the other second line drugs in the
management of JDM also has the benefit of steroid
sparing effect.
s
Rituximab, a monoclonal CD20+B cell-
depleting antibody, is another potential promising
new biologic agent in the management of JDM, its












Due to the effect and contribution of cytokine like
TNF-α in the pathophysiology of dermatomyositis,
the use of biologic agents in management of JDM is
currently gai The use of anti-TNF-α
has shown mixed results in the management of
ning ground .
JDM.
Three other criteria are necessary to make a definitive
diagnosis. Patients with the characteristic skin
eruptions who fulfill only two criteria are adjudged
to have probable JDM. The proposed criteria have
been expanded to include typical MRI and
ultrasonography findings, including affected muscle,
nail fold capillaroscopy, presence of calcinosis, and
dysphonia. The index patient had fulfilled almost all
the above criteria except the tests that could not be
done due to lack of necessary facilities. The
symptoms, signs and skin eruptions found in the
patient were typical of JDM. The median time for
diagnosis after onset of the disease was put at four
months, diagnosis was made 8 months into the
illness in our patient. The delay in diagnosis was due
to late presentation, referral, and lack of suspicion of
the disease, due to its rare occurrence.
Although the cause of JDM is not known, infection-
triggered autoimmunity has been proposed as a
possible precipitating factor. Infectious agents
implicated include coxsackie B virus, parvovirus
B19, enteroviruses, and species.
Preceding history of sore throat was obtained in the
patient, so also elevated ASO titre. It is probable
therefore that a streptococcal infection triggered the
autoimmunity in the patient. Noninfectious agents
implicated in the onset of JDM include D-
penicillamine, vaccinations, and bone marrow
transplants among other triggers.
Negative rheumatoid factor and anaemia are
common occurrence in patients with JDM.
Although, an elevated skeletal muscle creatinine
kinase (CK) is an important finding in patients, a
normal level does not exclude JDM as the enzyme
level is usually elevated in the early phase of the
disease, during the period of maximum muscle
inflammation and destruction. Pachman et al
reported that two out of five patients with definite
JDM had normal muscle enzyme when re-evaluated
some months later, though they had elevated enzyme
levels initially at the time of diagnosis. The patient
presented to us eight months into the illness and had a
normal total CK. It is possible that she had elevated
CK in the early phase of the disease consistent
withthe natural history of JDM. Other muscle
enzymes That may be elevated in JDM are aspartate
aminotransferase, lactic dehydrogenase and aldolase.
Radiographic MRI using T2 weighted images and fat
suppression localizes the active site of disease for
diagnostic muscle biopsy and electromyogram,
which are each non diagnostic in 20% of instances if
Not directed by MRI. The typical muscle biopsy











progression with a recurrence of active disease after a
prolonged remission have been reported.
The period of active symptoms has decreased from
about 3.5 years to less than 1.5 years with more
aggressive immunosuppressive therapy and a
mortality of about 1-10% was reported in western
literature. Prior to the advent of corticosteroids, it
was reported that one third of affected children died
and another one third were disabled. The outcome of
treatment of JDM in Nigeria is not known. Although
HUA had initial clinical improvement, sepsis set in
(but cultures were sterile) and scuttled the
management of the patient towards achieving
complete remission.
Even though, the health burden of rare disease
conditions like JDM on the Nigeria nation may be
low, its effect and burden on the affected family is
high, with attendant social and financial
implications. The challenges posed by this disease to
care givers especially in developing countries like
Nigeria are enormous. These concerns are depicted




Treatment adjuncts include calcium and vitamin D to
correct the osteopenia of JDM and to decrease the
frequency of bone fracture, avoidance of exposure to
sun and also use of sunscreen, to provide protection
against ultraviolet A and B. Antacids or H2
blockers, if dyspeptic symptoms are precipitated
bysteroids and antibiotics, especially for an infected
ulcer. Vitamin supplements may also be beneficial.
Physiotherapy provides passive stretching early
inthe disease and once active inflammation has
resolved, direct reconditioning of muscles to regain
strength and range of motion is initiated. Bed rest is
not indicated. Social work services may help
facilitate adjustment to the frustration of physical
impairment in a previously active child. Formation
of social support groups as in other chronic
debilitating illnesses may assist children with this
condition and their parents or care givers.The course
of JDM may be as brief as eight months
With complete recovery, or it can last two or more
years with a continuing requirement for treatment.
Acute exacerbations and remission without any
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